Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue

American Journal of Physiology - Cell Physiology

Volumn 307, Issue 1, 2014, Pages

  Colas, Romain A ^a   Shinohara, Masakazu ^a   Dalli, Jesmond ^a   Chiang, Nan ^a   Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Eicosanoids; Inflammation; Resolution; Resolvins

Indexed keywords

ACETYLSALICYLIC ACID; CD59 ANTIGEN; ESSENTIAL FATTY ACID; ICOSANOID; INFLAMMATORY LIPID MEDIATOR; LIPOXIN; MARESIN; MEDIATOR COMPLEX; OMEGA 3 FATTY ACID; RESOLVIN; SPECIALIZED PRO RESOLVING MEDIATOR; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; LIPID;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLOOD; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN TISSUE; ISOMER; LIPIDOMICS; LIQUID CHROMATOGRAPHY; LYMPHOID ORGAN; MALE; MAMMAL; METABOLOME; MIDDLE AGED; PHAGOCYTOSIS; PLASMA; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; VERY ELDERLY; IMMUNOLOGY; INFLAMMATION; LYMPH NODE; METABOLISM; METABOLOMICS; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ASPIRIN; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; DOCOSAHEXAENOIC ACIDS; ESCHERICHIA COLI; FATTY ACIDS, ESSENTIAL; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPIDS; LIPOXINS; LYMPH NODES; MALE; METABOLOMICS; MIDDLE AGED; PHAGOCYTOSIS; PRINCIPAL COMPONENT ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 84901937145     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00024.2014     Document Type: Article

References (49)

1. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201: 713-722, 2005.
2. Birnbaum Y, Ye Y. Pleiotropic effects of statins: the role of eicosanoid production. Curr Atheroscler Rep 14: 135-139, 2012.
3. Borgeson E, Godson C. Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol 3: 318, 2012.
4. Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 105: 1132-1141, 2013.
5. Calder PC. Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol 668, Suppl 1: S50-S58, 2011.
6. Chiang N, Fredman G, Backhed F, Oh SF, Vickery T, Schmidt BA, Serhan CN. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484: 524-528, 2012.
7. Claria J, Nguyen BT, Madenci A, Ozaki CK, Serhan CN. Diversity of lipid mediators in human adipose tissue depots. Am J Physiol Cell Physiol 304: C1141-C1149, 2013.
8. Cotran RS, Kumar V, Collins T (editors). Robbins Pathologic Basis of Disease. Philadelphia, PA: Saunders, 1999, p. 1425.
9. Dalli J, Serhan CN. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120: e60-e72, 2012.
10. 4H), and shifts macrophage phenotype. FASEB J 27: 2573-2583, 2013.
11. De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med 364: 2439-2450, 2011.
12. Di Giuseppe D, Wallin A, Bottai M, Askling J, Wolk A. Long-term intake of dietary long-chain n-3 polyunsaturated fatty acids and risk of rheumatoid arthritis: a prospective cohort study of women. Ann Rheum Dis. Epub ahead of print. doi: 10.1136/annrheumdis-2013-203338.
13. Fredman G, Oh SF, Ayilavarapu S, Hasturk H, Serhan CN, Van Dyke TE. Impaired phagocytosis in localized aggressive periodontitis: rescue by Resolvin E1. PLoS One 6: e24422, 2011.
14. Fullerton JN, O'Brien AJ, Gilroy DW. Lipid mediators in immune dysfunction after severe inflammation. Trends Immunol 35: 12-21, 2014.
15. Haeggstrom JZ, Funk CD. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 111: 5866-5898, 2011.
16. Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN, Van Dyke TE. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 179: 7021-7029, 2007.
17. Higgs GA, Salmon JA, Henderson B, Vane JR. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci USA 84: 1417-1420, 1987.
18. Hong S, Gronert K, Devchand P, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J Biol Chem 278: 14677-14687, 2003.
19. Isobe Y, Arita M, Matsueda S, Iwamoto R, Fujihara T, Nakanishi H, Taguchi R, Masuda K, Sasaki K, Urabe D, Inoue M, Arai H. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem 287: 10525-10534, 2012.
20. Janes KA, Yaffe MB. Data-driven modelling of signal-transduction networks. Nat Rev Mol Cell Biol 7: 820-828, 2006.
21. Jones ML, Mark PJ, Keelan JA, Barden A, Mas E, Mori TA, Waddell BJ. Maternal dietary omega-3 fatty acid intake increases resolvin and protectin levels in the rat placenta. J Lipid Res 54: 2247-2254, 2013.
22. Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, Kazani S, Israel E, Haley KJ, Serhan CN. Protectin D1 is generated in asthma and dampens airway inflammation and hyper-responsiveness. J Immunol 178: 496-502, 2007.
23. Lundstrom SL, Yang J, Brannan JD, Haeggstrom JZ, Hammock BD, Nair P, O'Byrne P, Dahlen SE, Wheelock CE. Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega-3 fatty acids. Mol Nutr Food Res 57: 1378-1389, 2013.
24. Mallat A, Lotersztajn S. Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis. Am J Physiol Cell Physiol 305: C789-C799, 2013.
25. Marchioli R, Schweiger C, Tavazzi L, Valagussa F. Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lipids36 Suppl: S119-S126, 2001.
26. Mas E, Croft KD, Zahra P, Barden A, Mori TA. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58: 1476-1484, 2012.
27. McFarlin BK, Williams RR, Venable AS, Dwyer KC, Haviland DL. Image-based cytometry reveals three distinct subsets of activated granulocytes based on phagocytosis and oxidative burst. Cytometry A 83: 745-751, 2013.
28. Miyata J, Fukunaga K, Iwamoto R, Isobe Y, Niimi K, Takamiya R, Takihara T, Tomomatsu K, Suzuki Y, Oguma T, Sayama K, Arai H, Betsuyaku T, Arita M, Asano K. Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma. J Allergy Clin Immunol 131: 353-360, 2013.
29. Morita M, Kuba K, Ichikawa A, Nakayama M, Katahira J, Iwamoto R, Watanebe T, Sakabe S, Daidoji T, Nakamura S, Kadowaki A, Ohto T, Nakanishi H, Taguchi R, Nakaya T, Murakami M, Yoneda Y, Arai H, Kawaoka Y, Penninger JM, Arita M, Imai Y. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 153: 112-125, 2013.
30. Morris T, Stables M, Colville-Nash P, Newson J, Bellingan G, de Souza PM, Gilroy DW. Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways. Proc Natl Acad Sci USA 107: 8842-8847, 2010.
31. Nakamura M, Shimizu T. Leukotriene receptors. Chem Rev 111: 6231-6298, 2011.
32. Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest 121: 569-581, 2011.
33. Pillai PS, Leeson S, Porter TF, Owens CD, Kim JM, Conte MS, Serhan CN, Gelman S. Chemical mediators of inflammation and resolution in post-operative abdominal aortic aneurysm patients. Inflammation 35: 98-113, 2012.
34. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS. The human serum metabolome. PLoS One 6: e16957, 2011.
35. Russell CD, Schwarze J. The role of pro-resolution lipid mediators in infectious disease. Immunology 141: 166-173, 2014.
36. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220: 568-575, 1983.
37. Serhan CN. A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem Cell Biol 122: 305-321, 2004.
38. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LAJ, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J 21: 325-332, 2007.
39. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192: 1197-1204, 2000.
40. Serhan CN (guest editor). Special Issue on Lipoxins and Aspirin-Triggered Lipoxins. Prostaglandins Leukot Essent Fatty Acids 73: 139-321, 2005.
41. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med 196: 1025-1037, 2002.
42. Serhan CN, Petasis NA. Resolvins and protectins in inflammationresolution. Chem Rev 111: 5922-5943, 2011.
43. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 49: 123-150, 2009.
44. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339: 166-172, 2013.
45. Tan ZS, Harris WS, Beiser AS, Au R, Himali JJ, Debette S, Pikula A, Decarli C, Wolf PA, Vasan RS, Robins SJ, Seshadri S. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology 78: 658-664, 2012.
46. Titos E, Claria J, Planaguma A, Lopez-Parra M, Villamor N, Parrizas M, Carrio A, Miquel R, Jimenez W, Arroyo V, Rivera F, Rodes J. Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. FASEB J 17: 1745-1747, 2003.
47. Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F, Pecker F, Tran A, Gual P, Mallat A, Lotersztajn S, Pavoine C. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 59: 130-142, 2014.
48. Weiss GA, Troxler H, Klinke G, Rogler D, Braegger C, Hersberger M. High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. Lipids Health Dis 12: 89, 2013.
49. Zhang MJ, Spite M. Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids. Annu Rev Nutr 32: 203-227, 2012.